Breathing treprostinil to slow progressive lung scarring
Treatments studied
Part of Lungs & breathing clinical trials.
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can sign informed consent
- Your CT scan (HRCT) within the last year shows lung fibrosis covering more than 10%
- You have progressive pulmonary fibrosis (not IPF) that worsened in the last 24 months despite standard treatment
- Your lung function test at screening shows FVC at least 45% predicted
- You will either stay on one approved anti-fibrosis pill (nintedanib or pirfenidone) or will not start either one during the study if you haven’t used them for at least 90 days
- If you use certain immune-suppressing medicines (like mycophenolate or methotrexate), you must be on them long enough and your doctor feels they have not helped
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
This trial tests an inhaled medication called treprostinil palmitil to see if it can slow the decline of lung function in people with progressive pulmonary fibrosis (PPF), a condition where lung scarring worsens over time. It's for people whose lung disease is getting worse despite standard care, and it may help preserve their breathing ability.
This study tests an inhaled powder medication called TPIP (treprostinil palmitil inhalation powder) to see if it can improve symptoms and exercise ability in people who have both interstitial lung disease and pulmonary hypertension. The study will compare TPIP against a placebo (a dummy treatment without the active drug) to understand how well it works and if it is safe.
This program provides access to an inhaled medication called treprostinil for people who have pulmonary hypertension (high blood pressure in the lungs) related to interstitial lung disease (a type of lung scarring). The treatment aims to improve symptoms and quality of life.
This study tests an experimental medicine called HSK44459 to see if it can slow down progressive pulmonary fibrosis (PPF), a condition that causes lung scarring and breathing difficulty. The goal is to learn if the medicine can help people keep more of their lung function compared to a placebo.
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
Hear when a new Progressive Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.